Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

摘要: BACKGROUND: Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy. Other activating RAS may also be negative predictive biomarkers for anti-EGFR METHODS: In this prospective-retrospective analysis, we assessed the efficacy and safety of panitumumab plus oxaliplatin, fluorouracil, leucovorin (FOLFOX4) as compared FOLFOX4 alone, according to (KRAS or NRAS) BRAF mutation status. A total 639 patients who had without results at least one following: 3 4; NRAS 2, 3, 15. The overall rate ascertainment status was 90%. RESULTS: Among 512 mutations, progression-free survival 10.1 months panitumumab-FOLFOX4 versus 7.9 alone (hazard ratio progression death combination therapy, 0.72; 95% confidence interval [CI], 0.58 0.90; P = 0.004). Overall 26.0 group 20.2 FOLFOX4-alone death, 0.78; CI, 0.62 0.99; 0.04). 108 (17%) non-mutated other mutations. These were associated inferior treatment, which consistent findings 2. a prognostic factor. No new signals identified. CONCLUSIONS: Additional predicted lack response received panitumumab-FOLFOX4. improvements observed therapy